Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Daniel J. O'Connor
|
| gptkbp:clinicalTrialPhase |
KEYNOTE-695
KEYNOTE-890 |
| gptkbp:collaboratesWith |
gptkb:Merck_&_Co.
|
| gptkbp:developedBy |
ImmunoPulse technology
TAVO (tavokinogene telseplasmid) |
| gptkbp:focusesOn |
immunotherapy
|
| gptkbp:foundedYear |
2011
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
OncoSec Medical
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:platform |
ImmunoPulse
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:specializesIn |
electroporation-based therapies
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
ONCS
|
| gptkbp:target |
melanoma
solid tumors |
| gptkbp:website |
https://oncosec.com
|
| gptkbp:bfsParent |
gptkb:CARIN_Alliance
gptkb:Sorrento_Mesa |
| gptkbp:bfsLayer |
8
|